ACSL3 and cancer: In the present study, we show that the expression of a lipid metabolism enzyme, ACSL3, classifies a group of NSCLC patients with poor survival, probably related to increased invasive properties moreover than proliferation‐related events, as previously shown of the involvement of lipid metabolism in cancer progression.